Angina Pectoris Drugs Market Size – By Type, By Drug Class, By Route of Administration, By Distribution Channel, Global Forecast, 2025 – 2034

Angina Pectoris Drugs Market Size

The global angina pectoris drugs market size was valued at USD 12.3 billion in 2024 and is estimated to grow at a CAGR of 4.1% from 2025 to 2034. The market growth is greatly attributed to the prevalence of cardiovascular diseases, new therapies, and the concern for a growing aging population.
 

One of the major contributors to market expansion is the trajectory of increasing lifestyle-related risk factors such as sedentary behavior, smoking, stress, and poor diets. Market growth is being fueled by these factors as they lead to a rise in heart diseases, which in turn increases the incidences of angina, high blood pressure, and diabetes. As modern lifestyles continue it results in poor heart health thus leading to more individuals at risk of angina and subsequently driving the demand for treatments.

Furthermore, the increase in diagnosis and awareness of angina, coupled with improved understanding of cardiovascular health, are also boosting market growth. Moreover, the expansion of healthcare access, particularly in developing countries, is allowing more people to seek treatment for angina. Therefore, with improvements in the infrastructure of healthcare worldwide, there is a growing availability of angina drugs, which stimulates the growth of this market.
 

Angina pectoris drugs are medications used to manage chest pains associated with angina pectoris and improve the overall performance of the heart by either improving blood flow or reducing the amount of oxygen used by the heart. Some of the most used classes of drugs are nitrates, beta-blockers, calcium channel blockers, anticoagulants, and antiplatelet agents. These drugs reduce symptoms, limit episodes, and help avoid more serious cardiovascular problems.
 

Angina Pectoris Drugs Market Trends

The increase in the number of people suffering from cardiovascular ailments is one of the factors boosting the growth of the market for angina pectoris medication.
 

• The British Heart Foundation states that approximately 620 million individuals globally are living with heart and circulatory conditions, with around 60 million new cases diagnosed every year. Globally, it is estimated that 1 in 13 individuals will have a heart or circulatory disease. These conditions are a leading cause of mortality, accounting for 1 in 3 deaths globally—around 20.5 million deaths in 2021, equivalent to 56,000 deaths per day or one death every 1.5 seconds.
   
• This high prevalence cardiovascular diseases and high mortality rate drives the demand for effective treatment options including angina pectoris drugs.
   
• Moreover, factors such poor nutrition, high body mass index, smoking, diabetes, and elderly populations contribute significantly to the growing prevalence of these diseases, thereby driving the market growth.
   
• In addition, the adoption of new technology helps to enhance the efficiency of medicines and other products, which in turn fosters the growth of the industry.
   

Angina Pectoris Drugs Market Analysis

Based on type, the global market is segmented into stable angina, unstable angina, microvascular angina, and prinzmetal angina. The stable angina segment accounted for significant market share of 51.3% in 2024.
 

• Stable angina is the most common type of angina, characterized by predictable chest pain that stretches from the heart and is triggered by emotional stress or physical movement. This type of angina is more prevalent among patients suffering with coronary artery disease, which supports the growth of this segment.
   
• The availability of well-established treatment options, including nitrates, beta blockers, and calcium channel blockers, supports effective management, further cements the adoption rates among drugs.
   
• Moreover, the awareness and introduction of new diagnostic technologies has led to more people being diagnosed with underlying angina, which further leads to the expansion of this segment.
   

Based on drug class, the angina pectoris drugs market is categorized into beta blockers, nitrates, anti-platelets, calcium channel blockers, anticoagulants, ACE inhibitors, and other drug classes. The beta blockers segment was valued at USD 3.7 billion in 2024.
 

• Beta blockers have been well identified as the gold standard treatment for angina pectoris, especially for the stable type where the heart rate is reduced, myocardial oxygen demand is lowered, and exercise tolerance is improved.
   
• In addition, the proven efficacy and widespread clinical applications of beta blockers further makes them a cornerstone for angina pectoris treatment.
   
• The growth of this segment is further sustained by rising prevalence of cardiovascular risk factors such as hypertension and coronary artery disease which requires beta blockers.

Based on route of administration, the angina pectoris drugs market is divided into oral, injectable, and topical. The oral segment dominated the market and is expected to grow at 4% CAGR over the analysis period.
 

• Most of the first-line treatments available for angina, like beta blockers, calcium channel blockers, and nitrates, are generally available in oral formulations, ensuring wide accessibility.
   
• Generally, compared to injectable forms, oral drugs are economical both for patients and the healthcare system because of lower manufacturing and distribution costs.
   
• Additionally, as long-term treatment is required for angina pectoris which eventually makes oral drugs ideal for daily use reducing the need for clinical visits.
   
• Owing to the above-mentioned factors the oral segment is anticipated to witness growth in the coming years.
   

Based on distribution channel, the angina pectoris drugs market is classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment accounted for 49.2% of market share in 2024.
 

• Patients suffering from unstable angina with accompanying comorbidities rely heavily on hospitals because of their expert cares, advanced drug formulations, injectable therapies, and comprehensive treatments plans. The highest growth of this segment is due to their ability to treat severe circumstances involving angina.
   
• In addition, the increase in cardiovascular issues has propelled the number of angina related problems giving rise to patients visiting the hospital which in return increases the demand for drugs from hospital pharmacies.

The U.S. angina pectoris drugs market was valued at USD 4.6 billion in 2024.
 

• As indicated by the National Institutes of Health, there are 10 million people suffering from angina in the U.S., which is a symptom of coronary artery disease, and roughly 500,000 people are diagnosed every year. This increasing prevalence drive the market for effective medications to manage angina and consequently leads to market growth.
   
• Furthermore, the U.S., being on the front lines of advanced medical research, offers a plethora of beta blockers, nitrates, and other advanced combination angina therapies. The growth of the market is also bolstered by these advancements that offer more effective treatment options.
   

Germany angina pectoris drugs market is predicted to witness remarkable growth over coming years.
 

• Germany's population is aging rapidly, with a significant portion above the age of 65. With an increase in the ageing population, the prevalence of cardiovascular diseases, including angina also increases, thus this demographic will continue to increase the demand for angina medications.
   
• Also, the country is well known for its highly advanced healthcare system with state-of-the-art treatment and medications. These factors, along with the globalization of new innovative therapies, allow the market for angina pectoris drugs to expand in Germany.
   

India is projected to grow significantly during the forecast period.
 

• The rise in the prevalence of cardiovascular diseases due to the growing rate of obesity, diabetes, hypertension, and a sedentary lifestyle has contributed to the growth of this market.
   
• In addition, the development of the healthcare infrastructure, increased healthcare awareness, and the implementation of schemes, for example, Ayushman Bharat, are making treatments for angina more widespread in the country, especially in the rural areas.
   

Brazil angina pectoris drugs market is expected to experience growth over the analysis period.
 

• Brazil’s ageing population is resulting in more individuals experiencing angina and other age-associated cardiovascular diseases. As the elderly segment of the population increases, there will be more people who will need heart-related medical care.
   
• Additionally, the country focus on expanding its healthcare system through programs like SUS (Sistema Único de Saúde), which provides affordable healthcare to a significant portion of the population. Thus, increasing the accessibility of angina pectoris drugs, leading to market growth.
   

Saudi Arabia angina pectoris drugs market is poised to grow in coming years.
 

• There are increasing rates of cardiovascular diseases in Saudi Arabia due to lesser engagement in exercise and more consumption of unhealthy food, accompanying this urbanization. This urbanization phenomenon will, however, fuel the growth of the market.
   
• Also, the development of this market is aided by factors like improved focus on awareness and preventive medicine, government healthcare schemes, and increasing rates of cardiovascular diseases.
   

Angina Pectoris Drugs Market Share

The market is quite competitive as different international pharmaceutical companies dominate the market. These companies allocate a substantial amount of funding towards research and development to provide better and more efficient treatment for angina over time. As more emphasis is placed on the health of the cardiovascular system, such joint ventures between pharmaceutical companies, practitioners, and research institutions are bound to foster innovation and positively impact the market in the future.
 

Angina Pectoris Drugs Market Companies

Few of the prominent players operating in the angina pectoris drugs industry include:

• AdvaCare Pharma
• Amgen
• AstraZeneca
• Bayer
• Boehringer Ingelheim International
• Eli Lilly and Company
• Gilead Sciences
• GlaxoSmithKline
• Merck
• Novartis
• Otsuka Pharmaceutical
• Pfizer
• Sanofi
   

USPs for top players:

• Expansion of product portfolios through mergers, acquisitions, and strategic collaborations.
   
• Focus on enhancing global market presence by targeting emerging and developed markets.
   
• Focus on affordability and accessibility of medications, particularly in underserved regions.
   

Angina Pectoris Drugs Industry News

• In March 2022, Zydus Lifesciences received final approval from the U.S. FDA to market nitroglycerin sublingual tablets in 0.3 mg, 0.4 mg, and 0.6 mg. These tablets are indicated for the relief of chest pain (angina) in patients with coronary artery disease. This approval helped the company to broaden its product portfolio and boost revenue growth.
   

The angina pectoris drugs market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Stable angina
• Unstable angina
• Microvascular angina
• Prinzmetal angina

Market, By Drug Class

• Beta blockers
• Nitrates
• Anti-platelets
• Calcium channel blockers
• Anticoagulants
• ACE inhibitors
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable
• Topical

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE